Carl Borrebaeck
31 – 40 of 322
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2016
-
Mark
Animal-Friendly Affinity Reagents : Replacing the Needless in the Haystack
(
- Contribution to journal › Scientific review
-
Mark
Animal-based antibodies : Obsolete
(
- Contribution to journal › Letter
-
Mark
Plasma protein profiling in a stage defined pancreatic cancer cohort – Implications for early diagnosis
(
- Contribution to journal › Article
-
Mark
Technical advances of the recombinant antibody microarray technology platform for clinical immunoproteomics
(
- Contribution to journal › Article
-
Mark
Plasma immunoprofiling of patients with high-risk diffuse large B-cell lymphoma : a Nordic Lymphoma Group study
(
- Contribution to journal › Article
-
Mark
Evaluation of Solid Supports for Slide- and Well-Based Recombinant Antibody Microarrays
(
- Contribution to journal › Article
- 2015
-
Mark
Prediction of Chemical Respiratory Sensitizers Using GARD, a Novel In Vitro Assay Based on a Genomic Biomarker Signature.
(
- Contribution to journal › Article
-
Mark
Advanced technologies and diagnostic spin-outs: an interview with Carl Borrebaeck.
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Combination of novel HER2-targeting antibody 1E11 with trastuzumab shows synergistic antitumor activity in HER2-positive gastric cancer.
(
- Contribution to journal › Article
-
Mark
A Multicenter Trial Defining a Serum Protein Signature Associated with Pancreatic Ductal Adenocarcinoma.
(
- Contribution to journal › Article